Compare ClearPoint Neuro Inc (CLPT) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Danaher Corporation — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $495.13M), while Danaher Corporation trades at $199.47 (market cap $141.67B). The key difference: Danaher Corporation is far larger — about 286.1× ClearPoint Neuro Inc's market cap, and Danaher Corporation pays a 0.8% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | DHR | |
|---|---|---|
Market Cap | $495.13M | $141.67B |
Sector | Health | Health |
52-Week High | $29.60 | $242.05 |
52-Week Low | $8.66 | $161.91 |
Enterprise Value | $523.12M | $154.45B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
